From Aug. 1 to the end of the year, Medicaid beneficiaries received 33,035 claims for GLP-1 drugs for weight loss, a number ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that weight loss drugs like Ozempic and Wegovy can serve another purpose for ...

Weight-loss drugs have exploded in popularity - but a full understanding of everything they touch in the body is still coming together. "This is new territory," said lead researcher Dr Ziyad al ...

exercise or start new diets. It stands to reason that some of these resolutions might also lead to increased demand for weight-loss prescriptions such as GLP-1 drugs. If the logic is even half ...